주사용 항당뇨병약 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the injectable anti-Diabetic drugs market size is expected to grow from USD 39.95 billion in 2025 to USD 41.14 billion in 2026 and is forecast to reach USD 47.63 billion by 2031 at 2.98% CAGR over 2026-2031.

This report is Segmented by Drug Class (Insulin [Basal/Long-acting, and More], GLP-1 Receptor Agonists), Diabetes Type (Type-1 Diabetes, Type-2 Diabetes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Age Group (Adults, Geriatric, Pediatric), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Injectable Anti-Diabetic Drugs Market Trends and Insights

Rising Diabetes & Obesity Prevalence

Global diabetes prevalence climbed from 6.1% in 2021 to a projected 9.8% by 2050, with 80% of patients living in developing countries. China already reports 233 million diabetics, equating to 15.88% of its population, and that figure could reach 29.1% by mid-century if trends persist. Regional phenotypes in Asia develop diabetes at lower BMI thresholds than Western peers, pushing demand for injectables at earlier disease stages. Southeast Asia alone is expected to see cases rise from 80 million to 151 million by 2045, underscoring sustained volume potential for the Injectable Anti-Diabetic Drugs Market.

Launch of Once-Weekly Injectable Therapies

Insulin icodec's approvals in the EU, Canada and Australia introduced a 196-hour half-life basal insulin that matches daily degludec efficacy while trimming injection frequency from seven to one . Patient satisfaction scores improve, though Type-1 users register higher hypoglycemic episodes, highlighting the need for careful titration. Pipeline assets such as IcoSema and Eli Lilly's efsitora alfa aim to blend basal insulin with semaglutide-like benefits, while triple-agonists under development promise broader metabolic control. These innovations widen therapeutic choice and spur switch-over growth within the Injectable Anti-Diabetic Drugs Market.

High Cost of Branded GLP-1 Analogues

GLP-1 receptor agonists list near USD 12,000 annually, creating affordability hurdles even where clinical benefits are clear. Competitive launches have raised rather than lowered prices, and meaningful reductions are unlikely until generics appear after 2031. Brazil is preparing for semaglutide copycats once patents lapse in 2026, while the United States has only just seen its first generic liraglutide approval. Until broader biosimilar penetration materializes, price sensitivity will temper volumes in price-elastic segments of the Injectable Anti-Diabetic Drugs Market.

Other drivers and restraints analyzed in the detailed report include:

1. Favourable Reimbursement in OECD Markets
2. Dual GIP/GLP-1 Agonist Pipeline Momentum
3. Cold-Chain & Last-Mile Logistics Gaps

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Insulin retained 59.12% of Injectable Anti-Diabetic Drugs Market share in 2025, reflecting its bedrock role in glycemic control. Revenue, however, advances gently as long-acting analogs cannibalize older human formulations and biosimilar competition spreads across emerging regions. Weekly insulin icodec's rollout adds a premium niche that may slow volume but raise value. Ultra-rapid prandial insulins now carve share within post-meal management, yet they face overlap with incretin-based weight management options that reduce insulin dose requirements.

The GLP-1 receptor agonist segment represents the growth engine, expanding at 3.74% CAGR through 2031. Semaglutide and tirzepatide lead with strong weight-loss efficacy, driving dual diabetes-obesity adoption despite temporary supply shortages. Second-generation assets targeting multiple receptors aim to elevate efficacy while prolonging dosing intervals. As cardiovascular-label expansions arrive, GLP-1s evolve into broader metabolic solutions, amplifying their influence on the Injectable Anti-Diabetic Drugs Market.

Type-2 diabetes constituted 80.05% of the Injectable Anti-Diabetic Drugs Market size in 2025, underlining the pandemic-like scale of adult-onset disease. Incremental prevalence gains and earlier initiation of injectables, especially GLP-1s, underpin volume stability. Automated basal-bolus dosing systems newly cleared for Type-2 users simplify regimens, encouraging uptake among tech-literate populations.

Type-1 diabetes, while smaller, grows marginally faster at 3.79% CAGR as pump-sensor ecosystems, weekly basal insulins and curative cell therapies pipeline create optimism. Clinical trials for islet cell replacement and gene-edited hypo-immune approaches suggest future disruption, yet near-term revenue stems from premium connected devices that extend the Injectable Anti-Diabetic Drugs Market.

Complete Report Scope:

• By Drug Class
  • Insulin
    • Basal/Long-acting
    • Bolus/Fast-acting
    • Traditional Human
    • Combination
    • Biosimilar
  • GLP-1 Receptor Agonists
    • Dulaglutide
    • Exenatide
    • Liraglutide
    • Lixisenatide
    • Semaglutide
• By DiabetesType
  • Type-1 Diabetes
  • Type-2 Diabetes
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Age Group
  • Adults
  • Geriatric
  • Pediatric
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America retained 40.05% of revenue in 2025, bolstered by leading-edge launches, extensive insurance frameworks and domestic production expansion. Insulin icodec secured Health Canada approval ahead of anticipated U.S. entry, while the FDA green-lit automated dosing systems for Type-2 users, reflecting regulatory openness. Investment totaling over USD 9 billion across two states is doubling fill-finish capacity, yet payer scrutiny and prior authorizations dampen growth momentum.

Asia-Pacific is the fastest-growing region at a 3.72% CAGR, a trajectory driven by China's 233 million diabetics and supportive policy in India that incentivizes local drug makers. Regional manufacturing collaborations, such as Novo Nordisk's tie-up with Bio Farma in Indonesia, drive cost-down strategies and boost access. Unique phenotypic factors that ignite diabetes at lower BMI thresholds and the expansion of urban middle-income groups further catalyze demand across the Injectable Anti-Diabetic Drugs Market.

Europe maintains stable expansion as biosimilar insulin approvals and EMA guideline updates foster competitive pricing and technological integration. Coordinated responses to GLP-1 shortages, including production scale-ups and discouragement of cosmetic off-label use, protect therapy availability. Investments by Sanofi and Novo Nordisk in continental facilities anchor supply chains, while emerging Latin American and Middle Eastern markets replicate Asia's localization model to bridge affordability gaps.

1. Novo Nordisk
2. Eli Lilly and Company
3. Sanofi
4. Biocon
5. Pfizer
6. Julphar
7. AstraZeneca
8. Amgen
9. Amylin Pharma
10. Zealand Pharma
11. Boehringer Ingelheim
12. Hanmi Pharmaceutical
13. Tonghua Dongbao
14. Gan & Lee
15. Wockhardt
16. Celltrion
17. Ypsomed
18. Insulet Corp
19. Medtronic
20. Beckton Dickinson
21. Hikma Pharma
22. Mylan-Viatris

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Diabetes & Obesity Prevalence
  • 4.2.2 Launch Of Once-Weekly Injectable Therapies
  • 4.2.3 Favourable Reimbursement in OECD Markets
  • 4.2.4 Dual GIP/GLP-1 Agonist Pipeline Momentum
  • 4.2.5 On-Body Wearable/Connected Injector Adoption
  • 4.2.6 Localised Insulin Manufacturing in Ems
• 4.3 Market Restraints
  • 4.3.1 High Cost of Branded GLP-1 Analogues
  • 4.3.2 Cold-Chain & Last-Mile Logistics Gaps
  • 4.3.3 Supply Squeeze from Weight-Loss Off-Label Use
  • 4.3.4 Shift Of R&D Capital Toward Oral/Gene Options
• 4.4 Regulatory Landscape
• 4.5 Porters Five Forces Analysis
  • 4.5.1 Bargaining Power of Suppliers
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Threat of New Entrants
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Drug Class
  • 5.1.1 Insulin
    • 5.1.1.1 Basal/Long-acting
    • 5.1.1.2 Bolus/Fast-acting
    • 5.1.1.3 Traditional Human
    • 5.1.1.4 Combination
    • 5.1.1.5 Biosimilar
  • 5.1.2 GLP-1 Receptor Agonists
    • 5.1.2.1 Dulaglutide
    • 5.1.2.2 Exenatide
    • 5.1.2.3 Liraglutide
    • 5.1.2.4 Lixisenatide
    • 5.1.2.5 Semaglutide
• 5.2 By DiabetesType
  • 5.2.1 Type-1 Diabetes
  • 5.2.2 Type-2 Diabetes
• 5.3 By Distribution Channel
  • 5.3.1 Hospital Pharmacies
  • 5.3.2 Retail Pharmacies
  • 5.3.3 Online Pharmacies
• 5.4 By Age Group
  • 5.4.1 Adults
  • 5.4.2 Geriatric
  • 5.4.3 Pediatric
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Novo Nordisk
  • 6.3.2 Eli Lilly
  • 6.3.3 Sanofi
  • 6.3.4 Biocon
  • 6.3.5 Pfizer
  • 6.3.6 Julphar
  • 6.3.7 AstraZeneca
  • 6.3.8 Amgen
  • 6.3.9 Amylin Pharma
  • 6.3.10 Zealand Pharma
  • 6.3.11 Boehringer Ingelheim
  • 6.3.12 Hanmi Pharmaceutical
  • 6.3.13 Tonghua Dongbao
  • 6.3.14 Gan & Lee
  • 6.3.15 Wockhardt
  • 6.3.16 Celltrion
  • 6.3.17 Ypsomed
  • 6.3.18 Insulet Corp
  • 6.3.19 Medtronic
  • 6.3.20 BD
  • 6.3.21 Hikma Pharma
  • 6.3.22 Mylan-Viatris

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment